Cargando…
Extended Delay to Treatment for Stage III-IV Non–Small-Cell Lung Cancer and Survival: Balancing Risks During the COVID-19 Pandemic
BACKGROUND: Due to the coronavirus disease 2019 (COVID-19) pandemic, patients may encounter lung cancer care delays. Here, we sought to examine the impact of extended treatment delay for stage III-IV non–small-cell lung cancer on patient survival. MATERIALS AND METHODS: Using National Lung Screening...
Autores principales: | Mayne, Nicholas R., Bajaj, Simar S., Powell, Joseph, Elser, Holly C., Civiello, Barbara S., Fintelmann, Florian J., Li, Xiao, Yang, Chi-Fu Jeffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068243/ https://www.ncbi.nlm.nih.gov/pubmed/35660355 http://dx.doi.org/10.1016/j.cllc.2022.05.001 |
Ejemplares similares
-
The Impact of Extended Delayed Surgery for Indolent Lung Cancer or Part-Solid Ground Glass Nodules
por: Mayne, Nicholas R., et al.
Publicado: (2022) -
Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients
por: Aoude, Lauren G., et al.
Publicado: (2020) -
The cost of unresectable stage III or stage IV melanoma in Italy
por: Maio, Michele, et al.
Publicado: (2012) -
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
por: Mandalá, Mario, et al.
Publicado: (2021) -
Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study
por: Potter, Alexandra L, et al.
Publicado: (2022)